383 results about "Ovarian cancer cells" patented technology

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with ovarian cancer. The biological compositions can be used to retard the growth of ovarian cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

TADG-12 and CA125 are two proteins expressed with high specificity in ovarian cancer tumors. They thus would be potential antigens for immunotherapy in ovarian cancer. The invention is based on the discovery of peptides in TADG-12 and CA125 that can be used to induce an autologous T cell response that lyses ovarian cancer cells expressing TADG-12 or CA125. The peptides are contacted with dendritic cells in vitro to generate peptide-loaded dendritic cells. The peptide-loaded dendritic cells are contacted with T cells in vitro to amplify CD8+ T cells that recognize the peptide. At least one CA125 peptide and at least one TADG-12 peptide were found that amplified CD8+ T cells, even from cancer patients, that lysed autologous CA125-expressing or TADG-12-expressing tumor cells. The peptide-loaded dendritic cells can be administered to a cancer patient to amplify CD8+ T cells in vivo that attack the cancer cells. Alternatively, autologous CD8+ T cells can be amplified ex vivo and then infused into the cancer patient.

The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the phosphatidyl ethanolamine-polyethylene glycol2000-folic acid micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.

The invention relates to a method for establishing a paclitaxel (PTX)-resistant ovarian cancer cell model. The method comprises the following specific steps: intervening an OVCAR-3 cell and an SK-OV-3 cell by virtue of PTX, replacing a PTX-free culture medium, intervening the OVCAR-3 cell and the SK-OV-3 cell until growth of cells returns to be normal, namely, under the conditions that the cells stably grow, morphologies are full, no floating dead cells are produced and the passage density is 30%, enabling the cells to grow 90% in 3-5 days, starting to carry out normal passage and improving the concentration of PTX, wherein the intervention time for each time is 24 hours; and finally obtaining the PTX-resistant ovarian cancer cell model having the preservation numbers of CCTCC C2014203 and CCTCC C2014204. According to the method, by closely observing growth states of cells and selecting the intervention moment, the established cell model has higher level of drug-resistance coefficients and good resistance stability and can be used for the research on ovarian cancer drug-resistant mechanism, ovarian cancer drug-resistant reversion, prevention of chemotherapy resistance and the improvement on chemosensitivity.

A method for detecting a kallikrein 8 polypeptide associated with ovarian cancer in a patient is provided comprising detecting kallikrein 8 polypeptide in a sample from the patient. Methods are also provided for monitoring the progression of ovarian cancer in a patient, determining whether ovarian cancer has metastasized or is likely to metastasize in the future, and assessing the aggressiveness or indolence of ovarian cancer. In addition, methods for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, selecting an agent for inhibiting ovarian cancer in a patient, and assessing the ovarian cancer cell carcinogenic potential of a test compound are described. The invention also contemplates a method of treating a patient susceptible to, or having a cancer that expresses a kallikrein 8 polypeptide.

The invention discloses a preparation method of cherokee rose polysaccharide derivatives with an antitumor activity. The preparation method comprises the following steps: firstly smashing cherokee rose fruit, degreasing, removing oligosaccharide, lixiviating with hot water twice, then mixing extracts, filtrating, concentrating, precipitating and drying so as to obtain crude cherokee rose polysaccharide; adding diethylin ethyl amino ethyl (DEAE)-cellulose 52 to carry out static absorption for 30 minutes; washing with distilled water, filtering, and collecting filtrate so as to obtain the decolored crude cherokee rose polysaccharide; carrying out protein removal on a crude polysaccharide solution by using an enzyme method and a Sevag method; further separating the crude cherokee rose polysaccharide with the DEAE-cellulose 52, collecting, dialyzing, and freeze-drying so as to obtain cherokee rose polysaccharide; and finally, carrying out sulphating, carboxymethylation and hydrochloric acid degradation on the cherokee rose polysaccharide, and carrying out carboxymethylation on degradation products so as to obtain a plurality of cherokee rose polysaccharide derivatives. The plurality of cherokee rose polysaccharide derivatives have in vitro antitumor characteristics, and can be used for inhibiting the growth of three tumor cells, namely, ovarian cancer cells, liver cancer cells and rectal cancer cells.

The invention discloses 3-phenylcoumarin robustic acid as well as an extraction method and application thereof. 3-phenylcoumarin robustic acid has a structural formula as shown in the specification as well as a chemical name of 3-(p-methoxyphenyl)-4-hydroxy-5-methoxy-2', 2'-dimethyl-6,7-dihydropyrancoumarin, a molecular formula of C22H20O6, and relative molecular weight of 380. 3-phenylcoumarin robustic acid disclosed by the invention has anti-tumor and other biological activities, can be effectively applied in preparation of anti-tumor drugs and has very strong inhibition effect on human gastric cancer cells, liver cancer cell lines, human lung cancer cells, cervical cancer cells, ovarian cancer cells and the like, the extraction method is simple and feasible and the extraction efficiency is relatively high.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of ovarian cancer cells and be used as a pharmaceutical composition to inhibit the ovarian tumor growth.

The invention belongs to the technical field of analytical chemistry and a chemical sensor, and discloses an electrochemical sensor for diagnosis of an ovarian SKOV-3 cancer cell, relating to a preparation method of a sandwich-type immunosensor based on graphene and a DNA (deoxyribonucleic acid) marker and application of the same in medical diagnosis. Antigens (human ovarian cancer) are indirectly tested with a glassy carbon electrode modified by graphene / antibody / antigen / DNA-labeled antibody / complementary DNA through catalytic oxidation based on guanine bases and adenine bases. The high electronic conductivity of the graphene is adopted, and the cost of the antibody marker is reduced. The immunosensor prepared based on the technical scheme can also be applied in detection of other types of cells has a wide scope of application. The sensor has high sensitivity, can be prepared simply, can be applied in detection any cancer cell, and has good prospects of application in medical diagnosis.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.

The invention provides a whole blood-oriented ovarian carcinoma cell detection kit. The kit mainly comprises HE4 goat polyclonal antibodies capable of specifically recognizing the antigen of the ovarian carcinoma cell human epididymis protein (HE4), biotinylated bovine serum albumin (BSA)-folic acid (FA), streptavidin-modified nano magnetic beads (SA-IO), streptavidin-modified QDs (SA-QDs), biotinylated anti-HE4 rabbit anti-goat IgG, a connecting reagent and the like. The kit is capable of efficiently separating out the carcinoma cells in the whole blood of an ovarian carcinoma patient by virtue of the enrichment characteristic of the immunomagnetic beads, and realizing multiple-signal synergetic amplification by specially binding with the targeted ovarian carcinoma cells by use of the SA-QDs and a biotinylated HE4 antigen-antibody complex. The kit has high sensitivity and specificity, and has an extremely wide application prospect in early detection of the ovarian carcinoma.

A promoter domain of 1816 bp or 441 bp in the upstream side of exon 1B of IAI.3B gene has a specifically high promoter activity in ovarian cancer cells. An adenovirus having this promoter domain inserted in the E1 domain thereof exhibits a specifically high cell proliferation inhibitory effect on ovarian cancer cells. Thus, it is efficacious in gene therapy for ovarian cancer.

Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

The invention belongs to the field of medical compounds and relates to a salicyloyl anilines compound as well as a preparation method and application in preparing an anti-cancer medicine. According to the method disclosed by the invention, the salicyloyl aniline is taken as a parent and different side-chain substituent groups are introduced into a benzene ring of the parent to prepare the salicyloyl anilines compound of the following formulas, wherein in the formulas, R1, R2, R3 and R4 are defined as an specification. Compared with the Lapatinib, the prepared salicyloyl anilines compound represents that the IC50 value is obviously reduced or is at least equal to that of the Lapatinib. The experiment shows that the salicyloyl anilines compound provided by the invention has an obvious inhibition effect on tumor cells, especially ovarian cancer cells so that the salicyloyl anilines compound can be further used for preparing antitumor medicines. The chemical formula of the salicyloyl anilines compound is represented by the following formulas.

The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1 / CXCL12). Examining the effects of glyceollin on in vivo tumor formation / growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma.

TADG-12 and CA125 are two proteins expressed with high specificity in ovarian cancer tumors. They thus would be potential antigens for immunotherapy in ovarian cancer. The invention is based on the discovery of peptides in TADG-12 and CA125 that can be used to induce an autologous T cell response that lyses ovarian cancer cells expressing TADG-12 or CA125. The peptides are contacted with dendritic cells in vitro to generate peptide-loaded dendritic cells. The peptide-loaded dendritic cells are contacted with T cells in vitro to amplify CD8+ T cells that recognize the peptide. At least one CA125 peptide and at least one TADG-12 peptide were found that amplified CD8+ T cells, even from cancer patients, that lysed autologous CA125-expressing or TADG-12-expressing tumor cells. The peptide-loaded dendritic cells can be administered to a cancer patient to amplify CD8+ T cells in vivo that attack the cancer cells. Alternatively, autologous CD8+ T cells can be amplified ex vivo and then infused into the cancer patient.

The invention provides application of PQBP1 in ovarian cancer diagnosis and treatment. The researches of the invention discovers that PQBP1 is high in expression in ovarian cancer patients, and in-vivo and in-vitro functional tests show that the PQBP1 can promote the proliferation and invasive migration of ovarian cancer cells. In addition, the researches discover that the PQBP1 can affect the selective splicing of endogenous Bcl-x, to be more specific, the PQBP1 can promote the expression of apoptosis inhibiting transcript Bcl-xL and inhibit the expression of apoptosis promoting transcript Bcl-xS to finally inhibit the apoptosis of the ovarian cancer cells. The researches show that the PQBP1 is a splicing factor participating in ovarian cancer occurrence and development, can be used as the biological marker and treatment target of ovarian cancer and has a good actual application value.

The invention discloses an iridium complex constructed based on 8-hydroxyquinoline derivative and 2-phenylpyridine iridium dimer and a synthesis method and application thereof. The synthesis method ofthe iridium complex comprises the following steps: putting a 2-phenylpyridine iridium dimer and an 8-hydroxyquinoline derivative into an organic solvent, and performing reacting under a heating or non-heating condition to obtain the corresponding target complex. A test result of an applicant shows that the complex has remarkable biological activity (the activity is remarkably higher than that ofligands and cisplatin of cervical cancer and ovarian cancer cells) on cervical cancer and ovarian cancer cells, and meanwhile, the toxicity of the complex on human normal hepatocytes is extremely low(IC50 is greater than 80 [mu] M); and moreover, the complex disclosed by the invention can also be used for fluorescence localization in tumor cells, and can be developed into a targeting anti-cancerdrug for fluorescence localization targeting mitochondria.

The invention discloses an iridium complex and a synthesis method and application thereof. The synthesis method of the iridium complex comprises the steps that 5-chloro-8-hydroxyquinoline and a 7, 8-benzoquinoline iridium dimer are added in an organic solvent, reaction is conducted under the heating or non-heating condition, and a target compound is obtained; wherein the organic solvent is ethanol, or a composition of ethanol and one or more than two selected from water, acetone, dichloromethane, trichloromethane, dimethyl sulfoxide and N, N-dimethylformamide. It is shown by test results in the invention that the iridium complex has remarkable biological activity (the activity is obviously higher than that of cis-platinum) on cervical cancer and ovarian cancer cells, and meanwhile, the toxicity of the iridium complex on normal hepatocytes of human body is extremely low (IC50 is higher than 80<mu>M).

The invention discloses three low-toxicity iridium complexes, and a synthesis method and an application thereof. The synthesis method of the iridium complexes comprises the following steps: taking andputting a 3-methyl-2-phenylpyridine iridium dimer and an 8-hydroxyquinoline derivative into an organic solvent, and reacting under a heating or non-heating condition to obtain the corresponding target complexes. Test results of the applicant show that the complexes have remarkable biological activity (the activity is remarkably higher than that of ligands and cis-platinum of the complexes) on cervical cancer and ovarian cancer cells, have extremely low toxicity (IC50 is more than 80 [mu]M) on human normal hepatocytes, and are expected to be developed into anti-tumor drugs.

The present invention relates to the anti-cancer activity of IL-24 polypeptide molecules. IL-24 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-24 for decreasing proliferation of ovarian cancer cells, treating ovarian cancer, amongst other uses disclosed. IL-24 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.

The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53- / -, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+ / +, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.

The present invention relates to the anti-cancer activity of IL-19 polypeptide molecules. IL-19 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-19 for decreasing proliferation of ovarian cancer cells, treating ovarian cancer, amongst other uses disclosed. IL-19 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.

The invention provides application of gamabufotalin and a salt compound thereof in preparation of a medicine for treating gynecological tumor. By comparing in vitro anti-cancer experiments of a bufadienolide extract and monomeric compounds, namely the gamabufotalin, cinobufagin, bufalin and bufotalin as well as hydrochlorides or sulfates of the four compounds to four gynecological tumors, namely human ovarian cancer cells A2780, human ovarian cancer cells SK-OV-3, human cervical carcinoma cells and human endometrial cancer cells, an experimental result shows that the gamabufotalin has stronger activity against gynecological tumor cells than the bufadienolide extract and the monomeric compounds, namely the cinobufagin, the bufalin and the bufotalin, and the hydrochloride or the sulfate of the gamabufotalin has stronger activity against gynecological tumor cells than the hydrochlorides or the sulfates of three compounds, namely the cinobufagin, the bufalin and the bufotalin. The gamabufotalin and the salt compound thereof provided by the invention have the advantages of clear components, controllable quality, strong anti-cancer activity, and small adverse reaction, and are expect to be developed into a novel anti-cancer drug.

The invention provides the application of iridoid compound to the preparation of ovarian cancer resistance medicament. The iridoid compound is isovaleric acid base dihydro valerian element or isovaleric acid base dihydro valepotriate J which has the following structural formula. The experiments on the toxic and killing effect of the isovaleric acid base dihydro valerian element or the isovaleric acid base dihydro valepotriate J on the p 53 wild ovarian cancer cells A2780, the p53 mutated OVCAR-3 cells and the normal ovarian cells IOSE144 show that the isovaleric acid base dihydro valerian element or the isovaleric acid base dihydro valepotriate J has the selective toxic and killing effect on the ovarian cancer cells and can inhibit the proliferation of ovarian cancer cells and kill the ovarian cancer cells. The iridoid compound can be used as the active component to prepare the ovarian cancer resistance medicament. The invention provides the novel ovarian cancer treatment medicament for the clinical treatment of the ovarian cancer and brings the joyous news to the patients with the ovarian cancer. The iridoid compound has higher application value.

Disclosed are methods and assays for detection of low concentration analytes such as proteins in a sample, using beads. Specially coated beads allow for femtomolar sensitivity through strong near-infrared fluorescence enhancement on plasmonic beads having gold nanostructures in a coating. By selecting different bead sizes and labeling with different fluorophores of plasmonic beads for immobilization of different capture antibodies, multiplexed plasmonic beads can be used for simultaneous quantification of various markers down to 0.01 pg / mL sensitivity. Exemplified are human cytokine IL-6, IFN-gamma, IL-1 beta, VEGF and ovarian cancer biomarker CA-125. Using flow cytometry, a detection limit below that of glass bead based immunoassays by 2-3 orders of magnitude was achieved. The multiplexed plasmonic bead assay was used to simultaneously quantify cytokines and CA125 of ovarian cancer cell culture medium, demonstrating the potential of plasmonic bead based immunoassay for sensitive biological detection relevant to human diseases.

The invention discloses an anti-CA125 carbohydrate antigen nano-antibody. The nano-antibody has three unique complementarity determining regions CDR1, CDR2 and CDR3. The invention also discloses an application of the nano-antibody in the preparation of tumor treatment drug and tumor diagnosis reagents. The anti-CA125 nano-body has highly specific recognizing and binding ability to the CA125, has aremarkable ADCC effect on ovarian cancer cells, and can accurately image tumors in mouse bodies.

The invention discloses a method for constructing an ovarian cancer transplantation tumor model based on an organoid method, and belongs to the field of medicines. According to the invention, an "organoid" culture technology is adopted, and a micro-carrier is used as a support material for culturing a patient-derived ovarian cancer cell-3D material complex; then the cell-3D material complex is directly inoculated under the skin of a normal immune mouse, and a patient-derived ovarian cancer transplantation tumor model is constructed, so that a problem that immune-deficiency mice such as severecombined immunodeficiency (SCID) mice, nude mice and the like are adopted in existing human ovarian cancer transplantation tumor models, the price is high, breeding is difficult, the tumor forming rate is low and the like can be solved, especially a problem that the existing immune-deficiency mouse human ovarian cancer transplantation tumor model cannot reflect impotent effects of an organism immune system in occurrence and development processes of tumors is solved, and a problem that an immune-deficiency mouse human transplantation tumor model is long in tumor forming period and cannot meet drug allergy requirements of patients urgently needing clinic drug therapy is solved. The method is applied to the field of mouse model construction.

The invention discloses a method for studying the function and mechanism of an m6A reader YTHDF1 in ovarian cancer. The method comprises the following steps of studying the genetic variation and expression change of an m6A modification related gene in ovarian cancer to determine that the m6A reader YTHDF1 is a main study object; carrying out further studying on the function of YTHDF1 in ovarian cancer cells and mouse models; screening and determining a target gene of the YTHDF1 by comprehensively applying a plurality of high-throughput analysis methods; and carrying out further exploration onthe clinical application feasibility of taking the YTHDF1 as the ovarian cancer molecular target. The invention provides a theoretical basis for clarifying the relationship between m6A and ovarian cancer and defining the carcinogenic function of YTHDF1, and possibly provides a new effective target for clinical diagnosis and treatment of ovarian cancer.

The invention provides a novel antineoplastic drug shown in a molecular formula (I). The synthesis method of the drug is simple and convenient, and the drug can be quickly and efficiently synthesized through microwave-assisted one-pot four-component reaction. The synthesis method comprises the following specific steps: dissolving 2 mmol of p-hydroxybenzaldehyde, 2 mmol of 4-fluoroacetophenone or 4-chloropropiophenone and 2 mmol of malononitrile in 1,4-dioxane; then adding 4 mmol of ammonium acetate; performing microwave (300W)-assisted heating to 120 DEG C, and reacting for 20 minutes; and adding ice water into the reaction mixture to precipitate a product, and then recrystallizing to obtain the product, namely 2-amino-3-cyano pyridine. The compound obtained by the invention is a novel antineoplastic drug shown in the molecular formula (I), and has the activity of obviously inhibiting the proliferation of liver cancer, stomach cancer, mammary cancer, pancreatic cancer, brain cancer, lung cancer and ovarian cancer cells.